#Paris #France #health and wellness #Havas Health Network #GLP-1 Consultancy

Havas Health Network Launches GLP-1 Consultancy in Paris

In a notable move for the healthcare sector, Havas Health Network introduced its pioneering GLP-1 consultancy at a key event in Paris. The gathering, titled "Shape Shifting: A Close Look at the Health and Wellness Disruptor – GLP-1," took place on March 13, 2025, at the impressive Havas Village venue. This initiative is positioned at the intersection of health, creativity, and technology, reflecting the network's commitment to fostering innovation in the ever-evolving health landscape.

With a diverse array of thought leaders, branding specialists, and healthcare professionals in attendance, the event aimed to delve deep into the transformative potential of GLP-1 treatments, which are beginning to reshape the healthcare market across Europe. The program was inspired by the success of a previous event in New York, GLP101 Day, which focused on the burgeoning interest in GLP-1 medications and their implications for healthcare and consumer behavior.

Understanding GLP-1 Treatments

GLP-1, or Glucagon-Like Peptide-1, is a class of medications that has gained traction for its efficacy in managing weight loss and diabetes. These treatments are not just becoming a fixture in healthcare; they are influencing consumer habits and lifestyle changes in significant ways. As the global market for GLP-1 drugs is projected to hit $5.56 billion by 2030, the implications for health and wellness industries are profound.

Chloé Depiesse, Managing Director of Havas Health Network, spoke about the varying dynamics between the North American and European markets, noting how cultural differences will impact the adoption and success of GLP-1 treatments. "The North American and European markets, while sharing similarities, each have unique cultural and societal nuances. These factors will undeniably influence how treatments are received and integrated by various demographics," she pointed out. This maxim reflects Havas' strategic approach, which seeks to tailor solutions that resonate within local contexts while navigating the broader global landscape.

Anna Maria Marra, CEO for Europe at Havas Health Network, reiterated the consultancy's commitment to advancing the understanding of GLP-1 treatments. "Our strong network and expertise in the GLP-1 space will empower us to deliver innovative solutions that meet the evolving needs of the European market," said Marra. "The aim is to educate our clients and partners about the growing applications of these treatments and to help them harness the opportunities within this new landscape."

A Look Ahead

The focus on actionable insights was a critical theme throughout the event. Providing tools and intelligence to empower brand leaders in Europe was particularly emphasized, as GLP-1 medications continue to disrupt not only healthcare but also the broader consumer goods landscape. Havas Health Network's deep understanding of the market dynamics will be pivotal for companies looking to adapt and thrive in this transformative era.

In sum, the launch of Havas Health Network’s GLP-1 consultancy represents a significant step towards reshaping the health and wellness industry across Europe. As they move forward, the insights gained from industry leaders during events like these will stand to benefit healthcare providers, patients, and brand marketers alike, creating a foundation for informed decision-making in this burgeoning field.

For more information about Havas Health Network's offerings and insights into the GLP-1 consultancy, visit Havas Health Network to explore their extensive resources and reports, including the proprietary GLP-1 Prosumer Report.

Conclusion

As the discussion on GLP-1 treatments gains momentum, Havas Health Network is poised to be a guiding force in navigating this complex yet promising landscape, ultimately contributing to a healthier future through innovation and collaboration in the health sector.